|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 76.60 USD | -0.49% |
|
+39.83% | +180.89% |
| 07-28 | EARNINGS AND TRADING: Allergy Therapeutics names next executive chair | AN |
| 07-27 | Health Care Up Amid Deal Activity -- Health Care Roundup | DJ |
Company Valuation: Forte Biosciences, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 31.57 | 21 | 29.86 | 145.2 | 486.3 | 1,873 | - | - |
| Change | - | -33.49% | 42.17% | 386.3% | 234.91% | 285.11% | - | - |
| Enterprise Value (EV) | 31.57 | 21 | 29.86 | 145.2 | 486.3 | 1,873 | 1,873 | 1,873 |
| Change | - | -33.49% | 42.17% | 386.3% | 234.91% | 285.11% | 0% | 0% |
| P/E | -1.38x | -1.25x | - | -1.87x | -5.79x | -19.3x | -18.8x | -18.4x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0x | - | - | 0.1x | 1.2x | -6.78x | -7.89x |
| Capitalization / Revenue | - | - | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | - | - | - | -0x | -0x | -20.6x | -17.4x | -14.7x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -38.75 | -20 | - | -12.17 | -4.71 | -3.965 | -4.075 | -4.17 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | - | - | - | -36.6 | -70.66 | -91.11 | -107.4 | -127.6 |
| Net income 1 | -21.71 | -13.88 | - | -35.48 | -69.38 | -91.11 | -107.4 | -127.6 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 53.50 | 25.00 | 20.54 | 22.71 | 27.27 | 76.60 | 76.60 | 76.60 |
| Nbr of stocks (in thousands) | 590 | 840 | 1,453 | 6,393 | 17,831 | 24,447 | - | - |
| Announcement Date | 31/03/22 | 31/03/23 | 18/03/24 | 28/03/25 | 31/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -19.32x | - | - | - | 1.87B | |
| 21.25x | 6.51x | 14.24x | 1.5% | 56.54B | |
| 31.6x | 7.8x | 24.02x | 0.05% | 53.6B | |
| -17.91x | 4.18x | -7.32x | -.--% | 22.91B | |
| -38.6x | 12.23x | -36.05x | -.--% | 21.37B | |
| 25.45x | 4.98x | 13.18x | -.--% | 20.27B | |
| 24.28x | 4.73x | 15.36x | -.--% | 17.56B | |
| -737.38x | 35.03x | -3943.97x | -.--% | 14.75B | |
| 40.7x | 16.37x | 42.16x | 0.09% | 13.53B | |
| 16.68x | 4.82x | 11.24x | -.--% | 13.33B | |
| Average | -65.33x | 10.74x | -429.68x | 0.18% | 23.57B | |
| Weighted average by Cap. | -31.96x | 9.11x | -238.39x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- FBRX Stock
- Valuation Forte Biosciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
